原創翻譯:龍騰網 http://www.herwqr.shop 翻譯:科科 轉載請注明出處
論壇地址:http://www.herwqr.shop/bbs/thread-485650-1-1.html

Big pharma war: India slams US for crusading against cheap generics

Washington’s push for intellectual property rights in the pharma industry is an attack on India’s generic drug trade, New Delhi says as a US government report accuses India of distributing counterfeit drugs worldwide.

美國政府一份報告指責印度在全球范圍內銷售假藥,新德里方面表示,美國政府推動制藥行業的知識產權,是對印度仿制藥貿易的攻擊。

Authorities in New Delhi were appalled as the “Special 301 report” published by the United States Trade Representative (USTR) on Saturday pinpointed India – alongside China – as the leading global sources of counterfeit medicines. The document, which reviews the state of intellectual property protection around the world, also alleges that up to 20 percent of drugs sold on the Indian market are fake and represent a danger to public health and safety.

美國貿易代表辦公室上周六發布的《301特別報告》將印度和中國列為全球假冒藥品的主要來源國,新德里當局對此感到震驚。這份審查全球知識產權保護狀況的文件還聲稱,印度市場上銷售的藥品中,多達20%是假冒的,對公眾健康和安全構成威脅。



"At a time when medicine prices are soaring, the report undermines the efforts seeking to make medicines more affordable domestically. USTR’s push for more protection and enforcement of IP policies would keep medicine prices high globally and place lifesaving treatments out of reach for longer in developing countries.”

“在藥品價格飆升之際,這份報告削弱了讓各國人民更能負擔得起藥品的努力。美國貿易代表辦公室推動加強知識產權政策的保護和執行,將使全球藥品價格居高不下,使發展中國家更長時間內無法獲得挽救生命的治療。”

India is the largest producer of generic drugs in the world with its exports covering 40 percent of generic demand in the US and 25 percent of all medicine market in the UK. Its pharma market was valued at $33 billion in 2017 and is expected to reach $55 billion by 2020.

印度是世界上最大的仿制藥生產國,其出口產品占美國仿制藥需求的40%,占英國所有藥品市場的25%。2017年,它的制藥市場價值330億美元,預計到2020年將達到550億美元。